Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.33 |
| ▸ | CTSK | P43235 | 3/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18075353 | 1.00 | CTSL (0.36) | CTSLCA1CA2CA7HCRTR2 | |
| SCHEMBL18075308 | 0.94 | HCRTR2 (0.37) | CTSLCA1CA2CA7HCRTR2 | |
| SCHEMBL18075307 | 0.94 | HCRTR2 (0.37) | CTSLCA1CA2CA7HCRTR2 | |
| SCHEMBL627874 | 0.90 | CTSL (0.35) | CTSLCA1CA2CA7HCRTR2 | |
| SCHEMBL627872 | 0.90 | CTSL (0.35) | CTSLCA1CA2CA7HCRTR2 | |
| SCHEMBL627873 | 0.90 | CTSL (0.35) | CTSLCA1CA2CA7HCRTR2 | |
| SCHEMBL18075536 | 0.86 | CTSK (0.41) | CTSLCA1CA2CA7AAK1 | |
| SCHEMBL18075287 | 0.86 | CTSK (0.41) | CTSLCA1CA2CA7AAK1 | |
| SCHEMBL18075286 | 0.86 | CTSK (0.41) | CTSLCA1CA2CA7AAK1 | |
| SCHEMBL18075288 | 0.86 | CTSK (0.41) | CTSLCA1CA2CA7AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053212-B2 | Benzimidazole derivatives as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-07-06 | — | — | US | disclosed |
| US-20200039953-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-02-06 | — | — | US | disclosed |
| US-10442786-B2 | Benzimidazole derivatives as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-10-15 | — | — | US | disclosed |
| EP-3549939-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-10-09 | — | — | EP | disclosed |
| EP-3271349-B1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-05-15 | — | — | EP | disclosed |
| US-20180044317-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-02-15 | — | — | US | disclosed |
| EP-3271349-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-01-24 | — | — | EP | disclosed |
| WO-2016146738-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10442786-B2 | Benzimidazole derivatives as bromodomain inhibitors | BRD4, BRD1, BRPF3 | CTSL 4097/4885CA1 2846/4885CA2 1996/4885 |
| US-20200039953-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD1, BRPF3 | CTSL 4097/4885CA1 2846/4885CA2 1996/4885 |
| US-20180044317-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD1, BRPF3 | CTSL 4097/4885CA1 2846/4885CA2 1996/4885 |
| US-11053212-B2 | Benzimidazole derivatives as bromodomain inhibitors | BRD4, BRD1, BRPF3 | CTSL 4097/4885CA1 2846/4885CA2 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.